目的 为促进患者恢复减轻其疼痛感，临床探究氟比洛酚酯复合舒芬太尼用于烧伤镇痛的可行性。方法 选取我院 2015年1月-2016年3月期间80例因烧伤入院治疗的患者，按双盲法随机分为两组包括单一组40例、联合组40例。单 一组使用舒芬太尼镇痛，联合组在单一组用药基础上加用氟比洛酚酯，观察患者疼痛改善情况，同时对患者用药期 间不良反应情况进行统计。结果 单一组不良反应发生率为22.5%，联合组为10.0%，单一组较联合组用药期间不良 反应多（P＜0.05）。用药前两组患者疼痛感比较差别无意义（P>0.05）。用药后患者疼痛感均有明显降低，且用 药后联合组较单一组疼痛轻（P<0.05）。结论 临床对烧伤患者进行静脉自控镇痛时，为有效减轻患者疼痛感同时 降低不良反应发生率，可选择氟比洛酚酯复合舒芬太尼进行镇痛。

Objective To relieve the patient’s pain degree and explore the feasibility of Flurbiprofen Axetil and Sufentanil in the burnt patient’s analgesia. Methods 80 burnt patients treated from January 2015 to March 2016 in our hospital were selected. Based on the double-blind method, the subjects were randomly divided into two groups, 40 cases each group. The single group just took Sufentanil, the combined group took the combined therapy of Flurbiprofen Axetil and Sufentanil. The pain degree and adverse reactions were observed. Results The adverse event rate for single group (22.5%) was higher than combined group (10.0%) (P<0.05), before treatment, the pain degree for two groups was not significantly different (P>0.05), after treatment, the pain degree for combined group was milder than single group (P<0.05). Conclusion During the patient-controlled intravenous analgesia, the combined therapy of Flurbiprofen Axetil and Sufentanil can reduce the patient’s pain degree and adverse event rate in clinical practice.